Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma

Centre René Gauducheau, Bd. Jacques Monod, Nantes, St. Herblain, France.
Haematologica (Impact Factor: 5.87). 05/2010; 95(10):1738-44. DOI: 10.3324/haematol.2009.015917
Source: PubMed

ABSTRACT This retrospective pooled analysis of two phase III trials (MM-009/MM-010) compared clinical outcomes of patients who achieved a complete response or very good partial response to treatment with lenalidomide plus dexamethasone with the outcomes of those who only achieved a partial response.
Patients (n=353) received lenalidomide (25 mg/day for 21 days of each 28-day cycle) plus dexamethasone (40 mg on days 1-4, 9-12, and 17-20 for four cycles, and only on days 1-4 after the first four cycles). Time to response, duration of response, time-to-progression, overall survival, and adverse events were investigated for patients who had a complete or very good partial response and compared with those of patients who had a partial response.
At the time of unblinding, 32% of patients had achieved a complete or very good partial response and 28% had a partial response. Half (50.5%) of the patients who had a partial response as their initial response achieved a complete or very good partial response with further treatment. The probability of achieving a complete or very good partial response with continued lenalidomide treatment decreased with delayed achievement of a partial response (by cycle 4 versus later); however, it remained clinically significant. With an extended follow-up of 48 months, the median response duration, time-to-progression, and overall survival were longer in patients with a complete or very good partial response than in those with a partial response (24.0 versus 8.3 months, P<0.001; 27.7 versus 12.0 months, P<0.001; not reached versus 44.2 months, P=0.021, respectively). The benefit of a complete or very good partial response was independent of when it was achieved.
Continuing treatment with lenalidomide plus dexamethasone to achieve best response, in the absence of disease progression and toxicity, provided deeper remissions and greater clinical benefit over time for patients in this study.

Download full-text


Available from: Robert Douglas Knight, Mar 26, 2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We present the case of a 72-year-old woman diagnosed with multiple myeloma (MM) in 1992 and treated with lenalidomide plus dexamethasone (LD) as third-line therapy. The patient achieved a complete remission (CR) after 6 cycles of LD treatment, was treated with LD for almost 4 years, and has now been in CR for 5 years. This case illustrates the potential of lenalidomide for continuous treatment in MM, with side effects controllable through tailored patient management including step-wise dose adaptations.
    memo - Magazine of European Medical Oncology 04/2012; 5(1). DOI:10.1007/s12254-012-0331-6
  • [Show abstract] [Hide abstract]
    ABSTRACT: The medical treatment of multiple myeloma has significantly improved over the last few years. Lenalidomide is an immunomodulatory agent approved, in combination with dexamethasone, to treat this disease. The agent is well tolerated and results in disease improvement in 60% of treated patients. The overall outcome of patients who achieve a response is better than those who do not. However, attaining a response can take several months. Prolonged treatment has been associated with induction of responses of better quality and maintenance of responses, leading to better long-term outcomes. The clinical cases presented here illustrate how continued long-term administration of lenalidomide in combination with dexamethasone: 1) is effective for patients who are resistant to thalidomide, regardless of the type of prior therapy; 2) is suitable for patients with neuropathy and renal impairment: and finally 3) leads to a long lasting, clinically meaningful outcome when treatment is adapted to the best tolerated dose.
    Advances in Therapy 12/2011; 28(8). DOI:10.1007/s12325-011-0081-6 · 2.44 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Lenalidomide is a more potent and better tolerated immunomodulatory drug (IMiD) as compared to thalidomide, the first-in-class IMiD. The mechanism of action of lenalidomide in multiple myeloma (MM) includes direct antitumor, immunomodulatory, and regulatory effects on the plasma cell-bone marrow niche interaction. Lenalidomide in combination with dexamethasone has shown a significantly higher efficacy as compared to dexamethasone alone in the treatment of relapsed or refractory MM in terms of overall response (OR) rate, complete response (CR) rate, time to progression (TTP), and overall survival (OS). Dosing, duration, and overall benefit of dexamethasone combination remains to be elucidated in ad-hoc trials, which may impact the tolerability and efficacy of the recommended schedule of lenalidomide rescue treatment. Depth of response achieved with lenalidomide and dexamethasone is associated with improvements in response duration, TTP, and OS, regardless of when the response is achieved. Although the probability of achieving a CR or very good partial response (VGPR) decreases over time, patients who are able to tolerate treatment in the absence of disease progression continue to experience benefits. However, optimal duration of rescue treatment from the time-point of best response has not been formally established. Recent data from phase 3 clinical trials also suggest the benefit of single-agent lenalidomide as maintenance after first-line treatment, and of lenalidomide combination therapy with conventional chemotherapy or new agents as induction treatment, in both autologous stem cell transplantation (ASCT) eligible and ineligible MM patients. Concerns about second primary neoplasms have been recently raised, and need further investigation. Taken together, these facts open new clinical settings in which lenalidomide therapy may benefit MM patients and deepen IMiD knowledge, especially in the continued rescue treatment and maintenance settings. Further study is warranted to optimize treatment with IMiDs.
    Advances in Therapy 12/2011; 28(8). DOI:10.1007/s12325-011-0076-3 · 2.44 Impact Factor
Show more